NTRK3

U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for Lilly’s Retevmo® (selpercatinib) for Certain Patients with Solid Tumors

Retrieved on: 
星期一, 十月 9, 2023
Oncology, FDA, Health, Genetics, Pharmaceutical, Biotechnology, Eli Lilly and Company, Lung cancer, Food, Doctor of Philosophy, Biomarker, ROS1, Breast, RET, NTRK1, NGS, MD, NTRK2, FGFR2, TMB, NTRK3, Lilly, Cancer, Eli Lilly, Lung, Colon, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Foundation Medicine, Prostate, ALK, Patient, Pharmaceutical industry, Medical imaging

It also marks Foundation Medicine’s ninth approved companion diagnostic indication across 7 different fusion genes (ALK, ROS1, NTRK1, NTRK2, NTRK3, FGFR2, and now RET.)

Key Points: 
  • It also marks Foundation Medicine’s ninth approved companion diagnostic indication across 7 different fusion genes (ALK, ROS1, NTRK1, NTRK2, NTRK3, FGFR2, and now RET.)
  • The test currently has over 30 companion diagnostic indications, ranging from lung, breast, prostate, colon, and other solid malignancies.
  • The company also has 60% of all U.S. companion diagnostic approvals for next generation sequencing (NGS) testing.
  • This companion diagnostic approval is the latest in a series of collaborative efforts between Foundation Medicine and Lilly.

Potential New Targets Identified in Advanced Non-Alcoholic Fatty Liver Disease

Retrieved on: 
星期四, 一月 5, 2023
Liver cancer, Fibrosis, Cancer, Icahn School of Medicine at Mount Sinai, Fatty liver disease, Cirrhosis, Mouse, Protein, Weizmann Institute of Science, Lung, Research, Scar, Type 2 diabetes, Institute of Liver and Biliary Sciences, NTRK3, NASH, University of California, Glass, Division, NAFLD, Non-alcoholic fatty liver disease, Liver failure, Disease, Hepatic stellate cell, Tissue, Yale School of Medicine, Liver disease, Patient, Mount Sinai, Science Translational Medicine, Heart, University, Hypertension, University of Edinburgh, Hepatitis, P30, Doctor of Philosophy, Sammi, Cell, Liver, Therapeutic discovery project, Medical imaging, Pharmaceutical industry, Dietary supplement, MD, Medicine

NEW YORK, Jan. 5, 2023 /PRNewswire-PRWeb/ -- Using the latest technologies—including both single-nuclear sequencing of mice and human liver tissue and advanced 3D glass imaging of mice to characterize key scar-producing liver cells—researchers have uncovered novel candidate drug targets for non-alcoholic fatty liver disease (NAFLD). The research was led by investigators at the Icahn School of Medicine at Mount Sinai.

Key Points: 
  • Using the latest technologies—including both single-nuclear sequencing of mice and human liver tissue and advanced 3D glass imaging of mice to characterize key scar-producing liver cells—researchers have uncovered novel candidate drug targets for non-alcoholic fatty liver disease (NAFLD).
  • Utilizing these innovative methods, the investigators discovered a network of cell-to-cell communication driving scarring as liver disease advances.
  • NEW YORK, Jan. 5, 2023 /PRNewswire-PRWeb/ -- Using the latest technologies—including both single-nuclear sequencing of mice and human liver tissue and advanced 3D glass imaging of mice to characterize key scar-producing liver cells—researchers have uncovered novel candidate drug targets for non-alcoholic fatty liver disease (NAFLD).
  • They identified a shared number of 68 pairs of potential drug targets across the two species.

Global Molecular Diagnostics Market to Surpass US$ 35,500.8 Million by 2030 - Coherent Market Insights

Retrieved on: 
星期三, 七月 20, 2022
DNA, National, NGS, Cdx, Siemens Healthineers, Agilent Technologies, Abbott Laboratories, CRADA, Oncology, MammaPrint, Development, Biomarker, Partnership, Cooperative research and development agreement, NTRK3, TSO, National Cancer Institute, US, NTRK2, NTRK1, S.A, Cancer, Adoption, CAGR, IVD, Illumina, Inc., Technology, Company, Patient, Breast cancer, Analysis, XNA, Becton, Dickinson and Company headquarters, NCI, Medical imaging, Fine chemical, EU, Illumina

SEATTLE, July 20, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global molecular diagnostics market is estimated to be valued at US$ 14,772.2 million in 2022 and is expected to exhibit a CAGR of 11.6 % during the forecast period (2022-2030).

Key Points: 
  • SEATTLE, July 20, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global molecular diagnostics market is estimated to be valued at US$ 14,772.2 million in 2022 and is expected to exhibit a CAGR of 11.6 % during the forecast period (2022-2030).
  • Key Trends and Analysis of the Global Molecular Diagnostics Market:
    Increasing product launches by market players is expected to drive the global molecular diagnostics market over the forecast period.
  • Global molecular diagnostics market is expected to exhibit a CAGR of 11.6% during the forecast period due to increasing adoption of inorganic growth strategies such as agreements by market players.
  • Key players operating in the global molecular diagnostics market include Hologic,Inc., Grifols, S.A., Abbott Laboratories, Qiagen N.V., F. Hoffmann-La Roche Ltd., Siemens Healthineers, Becton, Dickinson and Company, Agilent Technologies, Inc., Meridian, Cepheid, and Beckman Coulter, Inc.

Global Molecular Diagnostics Market to Surpass US$ 35,500.8 Million by 2030 - Coherent Market Insights

Retrieved on: 
星期三, 七月 20, 2022
DNA, National, NGS, Cdx, Siemens Healthineers, Agilent Technologies, Abbott Laboratories, CRADA, Oncology, MammaPrint, Development, Biomarker, Partnership, Cooperative research and development agreement, NTRK3, TSO, National Cancer Institute, US, NTRK2, NTRK1, S.A, Cancer, Adoption, CAGR, IVD, Illumina, Inc., Technology, Company, Patient, Breast cancer, Analysis, XNA, Becton, Dickinson and Company headquarters, NCI, Medical imaging, Fine chemical, EU, Illumina

SEATTLE, July 20, 2022 /PRNewswire/ --According to Coherent Market Insights, the global molecular diagnostics market is estimated to be valued at US$ 14,772.2 million in 2022 and is expected to exhibit a CAGR of 11.6 % during the forecast period (2022-2030).

Key Points: 
  • SEATTLE, July 20, 2022 /PRNewswire/ --According to Coherent Market Insights, the global molecular diagnostics market is estimated to be valued at US$ 14,772.2 million in 2022 and is expected to exhibit a CAGR of 11.6 % during the forecast period (2022-2030).
  • Key Trends and Analysis of the Global Molecular Diagnostics Market:
    Increasing product launches by market players is expected to drive the global molecular diagnostics market over the forecast period.
  • Global molecular diagnostics market is expected to exhibit a CAGR of 11.6% during the forecast period due to increasing adoption of inorganic growth strategies such as agreements by market players.
  • Key players operating in the global molecular diagnostics market include Hologic,Inc., Grifols, S.A., Abbott Laboratories, Qiagen N.V., F. Hoffmann-La Roche Ltd., Siemens Healthineers, Becton, Dickinson and Company, Agilent Technologies, Inc., Meridian, Cepheid, and Beckman Coulter, Inc.

Invitae Launches its First CE-IVD Cancer Testing Kits In Europe

Retrieved on: 
星期三, 二月 16, 2022
Health, NYSE, Patient, Cancer, NTRK1, ALK, Liquid biopsy, Forward-looking statement, RNA, ESMO, Electric Bond and Share Company v. Securities and Exchange Commission, Solution, SAN, Genome, RET, Private Securities Litigation Reform Act, NTRK3, MET, Security (finance), NGS, Large-cell lung carcinoma, Anaplastic lymphoma kinase, DX, NTRK2, CGP, Marie Cassidy, Plasma, Cdx, ROS1, NSCLC, Precision medicine, Growth, DNA, Corporate development, Neoplasm, Gene, IVD, Oncology, Medical device, Pharmaceutical industry, Medical imaging, Vaccine, Invitae, Illumina

Invitae is delivering essential high quality innovation for precision oncology in the fight against cancer.

Key Points: 
  • Invitae is delivering essential high quality innovation for precision oncology in the fight against cancer.
  • "This is a major step toward our mission to bring comprehensive genetic information into mainstream medicine," said Vishal Sikri, President of Oncology at Invitae.
  • "We congratulate Invitae on its first CE-IVD cancer testing kits, a significant milestone."
  • Molecular pathology has never been more important as the fight against cancer shifts towards precision oncology and targeted therapies based on genomic testing.

Invitae Launches its First CE-IVD Cancer Testing Kits In Europe

Retrieved on: 
星期三, 二月 16, 2022
Health, NYSE, Patient, Cancer, NTRK1, ALK, Liquid biopsy, Forward-looking statement, RNA, ESMO, Electric Bond and Share Company v. Securities and Exchange Commission, Solution, SAN, Genome, RET, Private Securities Litigation Reform Act, NTRK3, MET, Security (finance), NGS, Large-cell lung carcinoma, Anaplastic lymphoma kinase, DX, NTRK2, CGP, Marie Cassidy, Plasma, Cdx, ROS1, NSCLC, Precision medicine, Growth, DNA, Corporate development, Neoplasm, Gene, IVD, Oncology, Medical device, Pharmaceutical industry, Medical imaging, Vaccine, Invitae, Illumina

SAN FRANCISCO, Feb. 16, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the availability of FusionPlex Dx® and LiquidPlex Dx™ in Europe, part of its industry-leading Anchored Multiplex PCR chemistry in-vitro diagnostic (IVD) products. Invitae is delivering essential high quality innovation for precision oncology in the fight against cancer.

Key Points: 
  • Invitae is delivering essential high quality innovation for precision oncology in the fight against cancer.
  • "This is a major step toward our mission to bring comprehensive genetic information into mainstream medicine," said Vishal Sikri, President of Oncology at Invitae.
  • "We congratulate Invitae on its first CE-IVD cancer testing kits, a significant milestone."
  • Molecular pathology has never been more important as the fight against cancer shifts towards precision oncology and targeted therapies based on genomic testing.

Global TRK Inhibitors Market, Drug Sales & Clinical Trials, & Dosage Insights Report 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
星期一, 十二月 6, 2021
Pharmaceutical, Health, Oncology, Clinical Trials, Genentech, NTRK1, NTRK2, Lung, Adoption, Cancer, Clinical trial, Awareness, Prevalence, Breast, Papillary thyroid cancer, AstraZeneca, TRK, Glioblastoma, Research, Adult, Metastasis, Patent, Biotechnology, Data, Ono Pharmaceutical, Therapy, Brain, Growth, NTRK3, Pharmaceutical industry

The "Global TRK Inhibitors Market, Drug Sales & Clinical Trials insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global TRK Inhibitors Market, Drug Sales & Clinical Trials insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • The report provides insights into the patent, price, dosage and sales analysis of the currently approved TRK inhibitors.
  • Keeping in mind the various driver and challenges, the future outlook of TRK inhibitors has also been analyzed in the report.
  • Global TRK Inhibitors Market, Drug Sales & Clinical Trials Insight 2026 Report Analysis & Data Highlights:
    Global TRK Inhibitors Market Opportunity Assessment: > USD 2 Billion
    Ongoing Clinical Trials Assessment by Status, Phase & Region